Related references
Note: Only part of the references are listed.Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data
Carole Bandiera et al.
JMIR RESEARCH PROTOCOLS (2021)
Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
Jenny Zheng et al.
TARGETED ONCOLOGY (2021)
Population Pharmacokinetics of Palbociclib in a Real-World Situation
Bernard Royer et al.
PHARMACEUTICALS (2021)
Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
Alexandre Le Marouille et al.
PHARMACEUTICS (2021)
Therapeutic drug monitoring of oral targeted antineoplastic drugs
Anna Mueller-Schoell et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer
Jonathan Wilkie et al.
CLINICAL BREAST CANCER (2020)
The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
Thierry Buclin et al.
FRONTIERS IN PHARMACOLOGY (2020)
Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer
Geoffrey Alan Watson et al.
CLINICAL BREAST CANCER (2019)
Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs
Evelina Cardoso et al.
CLINICAL PHARMACOKINETICS (2018)
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach
Wan Sun et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
Andrea Henrich et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
Laura M. Spring et al.
ONCOLOGIST (2017)
462PA POPULATION PHARMACOKINETIC (PK) ANALYSIS OF PALBOCICLIB (PD-0332991) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
W. Sun et al.
ANNALS OF ONCOLOGY (2017)
Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions
Wan Sun et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Remy B. Verheijen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib
R. Costa et al.
BREAST (2017)
Targeted therapies in breast cancer: New challenges to fight against resistance
Viviana Masoud et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2017)
Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
Wenyue Hu et al.
CLINICAL CANCER RESEARCH (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
Sunil Verma et al.
ONCOLOGIST (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Interdisciplinary Medication Adherence Program: The Example of a University Community Pharmacy in Switzerland
Melanie Lelubre et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development
R. V. Overgaard et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development-Part 2: Introduction to Pharmacokinetic Modeling Methods
Dr Mould et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
Pirana and PCluster: A modeling environment and cluster infrastructure for NONMEM
Ron J. Keizer et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2011)
Targeted therapies for breast cancer
Michaele J. Higgins et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
LE Friberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
